Authors:
Lenferink, AEG
Busse, D
Flanagan, WM
Yakes, FM
Arteaga, CL
Citation: Aeg. Lenferink et al., ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways, CANCER RES, 61(17), 2001, pp. 6583-6591
Authors:
Cariou, S
Donovan, JCH
Flanagan, WM
Milic, A
Bhattacharya, N
Slingerland, JM
Citation: S. Cariou et al., Down-regulation of p21(WAF1/CIP1) or p27(Kip1) abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells, P NAS US, 97(16), 2000, pp. 9042-9046
Authors:
Busse, D
Doughty, RS
Ramsey, TT
Russell, WE
Price, JO
Flanagan, WM
Shawver, LK
Arteaga, CL
Citation: D. Busse et al., Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity, J BIOL CHEM, 275(10), 2000, pp. 6987-6995
Authors:
Flanagan, WM
Wagner, RW
Grant, D
Lin, KY
Matteucci, MD
Citation: Wm. Flanagan et al., Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide, NAT BIOTECH, 17(1), 1999, pp. 48-52
Authors:
Fornaro, M
Tallini, G
Zheng, DQ
Flanagan, WM
Manzotti, M
Languino, LR
Citation: M. Fornaro et al., p27(kip1) acts as a downstream effector of and is coexpressed with the beta(1C) integrin in prostatic adenocarcinoma, J CLIN INV, 103(3), 1999, pp. 321-329